Quality of Life and Patient-Reported Outcomes in Clinical Trials

Is quality of life is a “must” endpoint in designing interventional clinical trials today? How should patient-reported outcomes (PROs) be approached from an organizational and operational standpoint?

These are just some of the questions that Christopher Booth, MD, and Michael Brundage, MSc, FRCPC, MD, of Queen’s University debate with Dr. Chadi Nabhan for this episode of Healthcare Unfiltered. They also discuss the timeline of when PROs became an important component of clinical trials, how PRO measures should differ across disease types and trials, how payers should be approached for discussion on PRO measures, whether toxicity of therapies are underestimated by providers, and much more.

This episode originally appeared on chadinabhan.com.